Merck KGAa
-
Merck KGaA Puts Up €160M for Drug to Rival DNA Damage Cancer Meds From AstraZeneca, Gilead
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover new drugs for cancer, neurology, and immunology.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Merck KGaA opens Shanghai innovation hub, pumps $14M into China seed fund
Another innovation hub, in the southern city of Guangzhou, is planned for November. To date, six startups in China and other Asian countries have taken part in the German drugmaker’s accelerator program.
-
Three PD-L1 inhibitors see setbacks in their development
Two drugs – Pfizer and Merck KGaA’s Bavencio and AstraZeneca’s Imfinzi – saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
-
Big data and big pharma giants join forces on cancer research effort
Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.
-
Morning Read: Merck KGaA’s oncology revolution, a litmus test on biotech IPOs
Blogging will be light today on MedCity News – most of the staff is off for the Columbus Day holiday.